RECURRENT CHOLANGIOCARCINOMA
Clinical trials for RECURRENT CHOLANGIOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT CHOLANGIOCARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT CHOLANGIOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for Tough-to-Treat bile duct cancer
Disease control OngoingThis study is testing whether a drug called sacituzumab govitecan can help people with advanced bile duct cancer that has returned or spread after previous treatments. The drug is designed to deliver chemotherapy directly to cancer cells while sparing healthy cells. About 15 part…
Matched conditions: RECURRENT CHOLANGIOCARCINOMA
Phase: PHASE2 • Sponsor: University of Kansas Medical Center • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
New drug duo enters early trial for Tough-to-Treat digestive cancers
Disease control OngoingThis early-stage study is testing a combination of two drugs, guadecitabine and durvalumab, in people with advanced cancers of the liver, pancreas, bile duct, or gallbladder that have spread. The main goals are to find the safest dose and see what side effects occur. Researchers …
Matched conditions: RECURRENT CHOLANGIOCARCINOMA
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
New hope for Tough-to-Treat cancers: drug trial targets specific genetic flaw
Disease control OngoingThis study is testing whether the drug olaparib can help control advanced cancers that have a specific genetic change (IDH1 or IDH2 mutation) and have stopped responding to standard treatments. It is enrolling adults with certain brain tumors, bile duct cancer, or other solid tum…
Matched conditions: RECURRENT CHOLANGIOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC